A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

CompletedOBSERVATIONAL
Enrollment

702

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

March 20, 2025

Study Completion Date

March 20, 2025

Conditions
Parkinson Disease
Interventions
DRUG

Equfina 50 mg

Equfina 50 mg tablets.

Trial Locations (27)

Unknown

Site #23, Wŏnju

Site #11, Ilsan

Site #22, Yongin-si

Site #06, Cheonan

Site #09, Jinju

Site #07, Yangsan

Site #08, Iksan

Site #17, Jeonju

Site #18, Jeonju

Site #26, Jeonju

Site #03, Cheongju-si

Site #05, Busan

Site #16, Daegu

Site #25, Daegu

Site #20, Daejeon

Site #19, Gwanju

Site #24, Incheon

Site #02, Jeju City

Site #21, Sejong

Site #01, Seoul

Site #04, Seoul

Site #10, Seoul

Site #12, Seoul

Site #13, Seoul

Site #14, Seoul

Site #15, Seoul

Site #27, Ulsan

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY